Jorge Sifuentes, MD
Family Medicine · Amarillo, TXNPI 1841297421
Payments from drug & device makers
Across 295 payments — averaging $15.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$976
- AstraZeneca$391
- Pfizer$359
- AbbVie$355
- Boehringer Ingelheim$346
- Lilly USA, LLC$238
- plus $2K from 29 others
What the payments were for
- Food & beverage$4,523100%
- Education$200%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 64 | $976 |
| AstraZeneca | 20 | $391 |
| Pfizer | 22 | $359 |
| AbbVie(2 entities) | 24 | $355 |
| Boehringer Ingelheim | 25 | $346 |
| Lilly USA, LLC | 13 | $238 |
| Sunovion Pharmaceuticals Inc. | 16 | $173 |
| Kowa Pharmaceuticals America, Inc. | 16 | $167 |
| Novartis | 9 | $142 |
| Axsome Therapeutics, Inc. | 7 | $136 |
| Sanofi-aventis U.S. LLC | 9 | $115 |
| Amarin Pharma, Inc. | 7 | $114 |
| Antares Pharma, Inc. | 6 | $108 |
| Astellas Pharma US Inc | 7 | $105 |
| Phathom Pharmaceuticals, Inc. | 5 | $90 |
| Johnson & Johnson | 6 | $82 |
| Verona Pharma, Inc. | 4 | $81 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $59 |
| Supernus Pharmaceuticals, Inc. | 4 | $59 |
| Clarus Therapeutics Inc. | 3 | $58 |
| Bayer | 3 | $53 |
| Vanda Pharmaceuticals Inc. | 2 | $50 |
| Zyla Life Sciences, Inc. | 3 | $42 |
| Eisai Inc. | 3 | $37 |
| Novo Nordisk | 2 | $27 |
| Mylan Specialty L.p. | 2 | $26 |
| Sumitomo Pharma America, Inc. | 1 | $26 |
| Idorsia Pharmaceuticals US Inc | 1 | $25 |
| Avanir Pharmaceuticals, Inc. | 1 | $19 |
| Xeris Pharmaceuticals, Inc. | 1 | $17 |
| Biohaven Pharmaceuticals, Inc. | 1 | $15 |
| Halozyme Inc | 1 | $14 |
| Kyowa Kirin, Inc. | 1 | $13 |
| Amgen | 1 | $13 |
| Athena Bioscience, LLC | 1 | $13 |
How this compares
$4,543 in reported general payments places this provider in the 85th percentile of 8,760 family medicine providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 93 | $87,304 |
| JardianceEmpagliflozin | 77 | $77,504 |
| OzempicSemaglutide | 43 | $48,016 |
| EliquisApixaban | 72 | $47,514 |
| MounjaroTirzepatide | 39 | $40,367 |
| TrulicityDulaglutide | 32 | $31,876 |
| FarxigaDapagliflozin Propanediol | 22 | $27,177 |
| MyrbetriqMirabegron | 33 | $26,454 |
| XareltoRivaroxaban | 15 | $8,336 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 152 | $6,046 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 33 | $4,700 |
| Potassium Chloride | 201 | $4,003 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 14 | $3,455 |
| Atorvastatin Calcium | 264 | $3,434 |
| Ventolin HfaAlbuterol Sulfate | 38 | $3,132 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta | $976 | $87,30493 claims |
| Boehringer IngelheimJardiance | $346 | $77,50477 claims |
| Lilly USA, LLCMounjaro, Trulicity | $238 | $72,24471 claims |
| Novo NordiskOzempic | $27 | $48,01643 claims |
| PfizerEliquis | $359 | $47,51472 claims |
| AstraZenecaFarxiga | $391 | $27,17722 claims |
| Astellas Pharma US IncMyrbetriq | $105 | $26,45433 claims |
| Johnson & JohnsonXarelto | $82 | $8,33615 claims |
| AbbVieSynthroid | $355 | $1,28714 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 8,760 family medicine providers in Texas.
Other family medicine in Amarillo
- Douglas DenhamSan Antonio$68.5M
- Vicki MillerPasadena$58.3M
- Hareshkumar BogharaDesoto$30.3M
- Earl MartinTomball$30.1M
- Lisa HollowayHouston$30.1M
- William SegerFort Worth$27.5M
- Veronica FragosoHouston$24.5M
- Joel SolisMcAllen$21.1M
- George AtieeSan Antonio$19.9M
- Bonnie ColvilleHouston$19.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.